# FDA PDUFA Date for Atacicept BLA in IgA Nephropathy Set for July 7, 2026

> fda · REPORTED · 2026-05-07

The FDA granted Priority Review to Vera Therapeutics' BLA for atacicept in adult IgAN patients with a PDUFA target action date of July 7, 2026, potentially making it the first approved therapy targeting both BAFF and APRIL in IgAN. The company is on track for a U.S. commercial launch in mid-2026 pending regulatory approval.

- Company: Vera Therapeutics
- Sector: therapeutics
- Primary source: https://www.sec.gov/Archives/edgar/data/0001831828/000119312526210351/vera-ex99_1.htm

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.